Drug intelligence / Profile preview

Arident

Development stage
Unknown
Lead developer
Ardent Life Sciences
Modality
Small Molecules
Administration
Oral
01

Overview

Arident is a branded formulation of aripiprazole, an atypical antipsychotic marketed by Ardent Life Sciences. It is indicated for the treatment of schizophrenia, manic episodes associated with bipolar I disorder, and as an adjunctive therapy for major depressive disorder. As a small molecule, Arident acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and as an antagonist at serotonin 5-HT2A receptors. This pharmacological profile, often referred to as a dopamine-serotonin system stabilizer, helps regulate neurotransmitter activity to alleviate both positive and negative symptoms of psychiatric disorders while minimizing the risk of extrapyramidal side effects. The drug is available in 5mg and 10mg tablet strengths and works by modulating dopamine overactivity in the brain.

Brand names
Arident
Other names
aripiprazole
02

Targets

HTR2A (Serotonin receptor 5-HT2A)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))DRD2 (Dopamine D2 Receptor)

Beyond the preview

Go deeper on Arident.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Arident.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call